Yupelri Availability Update: What Patients Need to Know in 2026

If you're a COPD patient taking Yupelri (revefenacin) — or if your doctor has recently recommended it — you may be wondering about its current availability. Reports of difficulty finding Yupelri at pharmacies are common, leading many patients to wonder whether there's a shortage. Here's the most up-to-date information for 2026.

Is Yupelri in a Shortage in 2026?

As of 2026, Yupelri is not listed on the FDA's official drug shortage database. The FDA defines a drug shortage as a period when the supply of a drug is inadequate to meet the demand. Yupelri does not meet this official definition.

However, "not in shortage" does not mean easy to find. Yupelri occupies a niche in the COPD medication market — it is a specialty nebulized product with limited retail distribution. Many patients encounter difficulty finding it at their local pharmacy, not because of a supply disruption, but because of limited stocking by retail pharmacies.

Why Is Yupelri So Hard to Find if There's No Shortage?

The availability challenge with Yupelri is structural — it's built into the nature of the drug, not a supply chain disruption. Several factors contribute:

Niche market: Yupelri holds approximately 2–3% of the inhaled COPD medication market, making it a low-volume product for most pharmacies.

High list price: At $1,655.34 per 30-day supply (WAC), pharmacies face significant inventory investment for an infrequently dispensed product.

No generic: Without a generic competitor, there's no price pressure to drive wider distribution. Generic entry is not expected until at least 2031.

Insurance prior authorization: Many insurers, including UnitedHealthcare, require step therapy — failure of tiotropium (Spiriva) must be documented before they cover Yupelri — which delays prescriptions reaching the pharmacy.

What Has Yupelri's Availability History Been Like?

Since its FDA approval on November 9, 2018, Yupelri has maintained a consistent but limited market presence. It has not been subject to major manufacturing disruptions or FDA-listed shortages. However, patient-reported difficulty finding it at retail pharmacies has been a persistent theme throughout its market history.

The medication transitioned from Theravance Biopharma/Mylan to Viatris Specialty LLC as manufacturer and distributor, which is standard following Mylan's merger with Upjohn (a Pfizer division) to form Viatris in 2020. This transition did not cause supply disruptions.

What Should Patients Do Right Now?

If you're currently taking Yupelri and worried about access, here are the most important steps to take in 2026:

Don't wait until you run out. Refill Yupelri 7–10 days before your current supply runs out. This gives you time to locate a pharmacy that has it in stock.

Consider switching to mail-order. Mail-order pharmacies through your insurance plan's pharmacy benefit manager (Express Scripts, CVS Caremark, Optum Rx) are more reliable for specialty medications like Yupelri. A 90-day supply removes monthly uncertainty.

Ask about specialty pharmacy options. Your pulmonologist's office can often refer you to a specialty pharmacy that reliably stocks Yupelri.

Confirm your prior authorization is active. Prior authorizations expire. Check with your insurance company to ensure your Yupelri prior auth is current so it doesn't delay a refill.

Use medfinder.com to check local pharmacy stock without spending hours on hold.

What to Do if You Run Out of Yupelri

If you've run out of Yupelri and can't locate a replacement supply immediately:

Contact your pulmonologist or prescriber right away — they may have samples or can call a specialty pharmacy directly.

Ask about a temporary bridge medication, such as ipratropium nebulizer solution (a short-acting anticholinergic widely available at pharmacies).

Do not use extra doses of your rescue inhaler (albuterol) as a long-term replacement for Yupelri — this is not medically equivalent.

Seek emergency care if you experience significant worsening of breathing, chest tightness, or shortness of breath that your rescue inhaler doesn't relieve.

Will Availability Improve?

Yupelri's availability is unlikely to dramatically improve in the short term without a generic entering the market. One tentative generic approval for revefenacin has been filed, but full generic market entry is not expected before 2031.

In the meantime, using medfinder.com to locate available stock, switching to mail-order, and working with a specialty pharmacy are the most reliable strategies. If access remains a persistent problem, talk to your doctor about whether a more widely available COPD medication might be right for your situation. See our article on alternatives to Yupelri for more details.